1. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. (29th January 2018) Authors: Knox, J J; Barrios, C H; Kim, T M; Cosgriff, T; Srimuninnimit, V; Pittman, K; Sabbatini, R; Rha, S Y; Flaig, T W; Page, R D; Beck, J T; Cheung, F; Yadav, S; Patel, P; Geoffrois, L; Niolat, J; Berkowitz, N; Marker, M; Chen, D; Motzer, R J Journal: Annals of oncology Issue: Volume 29:Number 11(2018) Page Start: 2269 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 870PDEfficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): Results of a GETUG multicenter phase II trial (Axipap). (23rd October 2018) Authors: Negrier, S; Rioux-Leclercq, N; Ravaud, A; Gravis, G; Geoffrois, L; Chevreau, C M; Rolland, F; Blanc, E; Segura-Ferlay, C; Perol, D; Gross Goupil, M; Dermeche, S; Flechon, A; Albiges, L; Escudier, B Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 868PDBrain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial. (23rd October 2018) Authors: Flippot, R; Dalban, C; Laguerre, B; Borchiellini, D; Gravis, G; Negrier, S; Chevreau, C M; Joly, F; Geoffrois, L; Ladoire, S; Mahammedi, H; Tantot, F; Escudier, B; Albiges, L Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗